Eli Lilly Acquires DICE Therapeutics

Eli Lilly Acquires Dermira for $1.1 Billion

January 10, 2020

Biotechnology

Eli Lilly agreed to acquire Dermira, Inc. in an all-cash transaction valued at approximately $1.1 billion ($18.75 per share). The deal adds Dermira's Phase 3 IL-13 antibody candidate lebrikizumab and marketed dermatology product QBREXZA to Lilly's immunology and dermatology portfolio and is expected to close in Q1 2020.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Eli Lilly Acquires Morphic

July 8, 2024

Biotechnology

Eli Lilly agreed to acquire Morphic Holding, Inc. for $57 per share (approximately $3.2 billion) to expand its immunology and gastroenterology pipeline with Morphic's oral integrin therapies, including MORF-057. Lilly commenced a tender offer that was completed (with subsequent second-step merger) and the transaction closed in August 2024.

Fever Acquires Ticketing Platform DICE

June 5, 2025

Media & Entertainment

Live-entertainment discovery platform Fever has acquired U.K.-based ticketing and discovery platform DICE. The deal follows Fever’s completion of a >$100M equity raise led by investors including L Catterton and Point72 Private Investments and is intended to combine DICE’s ticketing capabilities with Fever’s global discovery engine and audience to accelerate growth in music, sports and live events.

Eli Lilly Acquires POINT Biopharma Global

December 27, 2023

Biotechnology

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

Eli Lilly and Company Acquires Disarm Therapeutics

October 15, 2020

Biotechnology

Eli Lilly and Company agreed to acquire Cambridge-based Disarm Therapeutics for an upfront $135.0 million, with potential development, regulatory and commercial milestone payments of up to $1.225 billion. The acquisition adds Disarm's preclinical SARM1 inhibitor programs to Lilly's R&D efforts in pain and neurodegeneration to accelerate development of disease‑modifying therapies for axonal degeneration.